Full Press Release Details
Owens & Minor Reports First Quarter 2025 Financial Results
Top-Line Growth Led by the Patient Direct Segment
Patient Direct Operating Margin Expanded by 173 Basis Points
Company Reaffirmed 2025 Financial Guidance
Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment
RICHMOND, VA - May 8, 2025 - Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the first quarter ended March 31, 2025.
"Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen expansion in EBITDA for the segment. Our Products & Healthcare Services segment saw top-line growth in our Medical Distribution division, as well as good progress on driving profit improvement initiatives. We remain actively engaged in the sale process of our Products & Healthcare Services segment," said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor.
Pesicka concluded, "Looking ahead, our focus remains on disciplined capital deployment, working towards our leverage target, successfully navigating potential changes in government policy, including tariffs and integrating our planned acquisition of Rotech. We remain bullish on the outlook for our Patient Direct segment and the strengthening of our P&HS businesses."
| Financial Summary (1) | ||||||
| ($ in millions, except per share data) | 1Q25 | 1Q24 | ||||
| Revenue | $ | 2,632 | $ | 2,613 | ||
| Operating income, GAAP | $ | 0.1 | $ | 9.7 | ||
| Adj. Operating Income, Non-GAAP | $ | 61.3 | $ | 57.4 | ||
| Net loss, GAAP | $ | (25.0) | $ | (21.9) | ||
| Adj. Net Income, Non-GAAP | $ | 18.1 | $ | 14.9 | ||
| Adj. EBITDA, Non-GAAP | $ | 121.9 | $ | 116.3 | ||
| Net loss per common share, GAAP | $ | (0.32) | $ | (0.29) | ||
| Adj. Net Income per share, Non-GAAP | $ | 0.23 | $ | 0.19 |
(1) Reconciliations of the differences between the non-GAAP financial measures presented in this release and their most directly comparable GAAP financial measures are included in the tables below.
2025 Financial Outlook
The Company reaffirmed its financial guidance for 2025; summarized below:
The Company's outlook for 2025 excludes any impact of the previously announced Rotech acquisition, any potential transaction involving the Products & Healthcare Services segment, future share repurchase activity, and the potential positive or negative impact from any policy shifts, including additional tariffs and retaliatory actions taken in response to such tariffs. The outlook also contains assumptions, including current expectations regarding the impact of general economic conditions.
Although the Company does provide guidance for adjusted EBITDA and adjusted EPS (which are non-GAAP financial measures), it is not able to forecast the most directly comparable measures calculated and presented in accordance with GAAP without unreasonable effort. Certain elements of the composition of the GAAP amounts are not predictable, making it impracticable for the Company to forecast. Such elements include, but are not limited to, exit and realignment charges and acquisition-related charges, which could have a significant and unpredictable impact on our GAAP results. As a result, no GAAP guidance or reconciliation of the Company's adjusted EBITDA guidance or adjusted EPS guidance is provided. The outlook is based on certain assumptions that are subject to the risk factors discussed in the Company's filings with the SEC.
Investor Conference Call for First Quarter 2025 Financial Results
Owens & Minor will host a conference call for investors and analysts on Thursday, May 8, 2025, at 8:00 a.m. EDT. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above.
This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC's Fair Disclosure Regulation. This release contains certain "forward-looking" statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our financial performance, our 2025 financial results, Owens & Minor's ability to successfully complete the sale of the P&HS business in any specific transaction on favorable terms or at all, the risk that the proposed acquisition of Rotech will not be consummated in a timely manner or at all, our cost-saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to Owens & Minor's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 28, 2025, including the section captioned "Item 1A. Risk Factors," as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company's actual results to differ materially from its current estimates. These filings are available at www.owens-minor.com. Given these risks and uncertainties, Owens & Minor can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Owens &
Minor specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
*Registered Trademark or Trademark of O&M Halyard or its affiliates.
Consolidated Statements of Operations (unaudited)
(dollars in thousands, except per share data)
| Three Months Ended March 31, | ||||||
| 2025 | 2024 | |||||
| Net revenue | $ | 2,632,048 | $ | 2,612,680 | ||
| Cost of goods sold | 2,106,035 | 2,077,151 | ||||
| Gross profit | 526,013 | 535,529 | ||||
| Distribution, selling and administrative expenses | 462,352 | 477,613 | ||||
| Acquisition-related charges and intangible amortization | 29,674 | 20,313 | ||||
| Exit and realignment charges, net | 31,226 | 27,356 | ||||
| Other operating expense, net | 2,637 | 551 | ||||
| Operating income | 124 | 9,696 | ||||
| Interest expense, net | 33,959 | 35,655 | ||||
| Other expense, net | 1,239 | 1,153 | ||||
| Loss before income taxes | (35,074) | (27,112) | ||||
| Income tax benefit | (10,092) | (5,226) | ||||
| Net loss | $ | (24,982) | $ | (21,886) | ||
| Net loss per common share: | ||||||
| Basic | $ | (0.32) | $ | (0.29) | ||
| Diluted | $ | (0.32) | $ | (0.29) |
Condensed Consolidated Balance Sheets (unaudited)
(dollars in thousands)
| March 31, 2025 | December 31, 2024 | |||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 59,436 | $ | 49,382 | ||
| Accounts receivable, net | 580,175 | 690,241 | ||||
| Merchandise inventories | 1,408,539 | 1,131,879 | ||||
| Other current assets | 158,048 | 149,515 | ||||
| Total current assets | 2,206,198 | 2,021,017 | ||||
| Property and equipment, net | 520,332 | 509,347 | ||||
| Operating lease assets | 383,111 | 355,627 | ||||
| Goodwill | 1,331,931 | 1,331,281 | ||||
| Intangible assets, net | 285,086 | 298,726 | ||||
| Other assets, net | 129,766 | 140,158 | ||||
| Total assets | $ | 4,856,424 | $ | 4,656,156 | ||
| Liabilities and equity | ||||||
| Current liabilities | ||||||
| Accounts payable | $ | 1,380,736 | $ | 1,228,691 | ||
| Accrued payroll and related liabilities | 87,388 | 151,039 | ||||
| Current portion of long-term debt | 49,947 | 45,549 | ||||
| Other current liabilities | 442,144 | 426,773 | ||||
| Total current liabilities | 1,960,215 | 1,852,052 | ||||
| Long-term debt, excluding current portion | 1,897,515 | 1,808,047 | ||||
| Operating lease liabilities, excluding current portion | 324,032 | 286,212 | ||||
| Deferred income taxes, net | 16,307 | 22,456 | ||||
| Other liabilities | 87,376 | 101,025 | ||||
| Total liabilities | 4,285,445 | 4,069,792 | ||||
| Total equity | 570,979 | 586,364 | ||||
| Total liabilities and equity | $ | 4,856,424 | $ | 4,656,156 |
Consolidated Statements of Cash Flows (unaudited)
(dollars in thousands)
| Three Months Ended March 31, | ||||||
| 2025 | 2024 | |||||
| Operating activities: | ||||||
| Net loss | $ | (24,982) | $ | (21,886) | ||
| Adjustments to reconcile net loss to cash provided by operating activities: | ||||||
| Depreciation and amortization | 61,153 | 74,095 | ||||
| Share-based compensation expense | 6,928 | 6,866 | ||||
| Deferred income tax benefit | (6,240) | (3,659) | ||||
| Changes in operating lease right-of-use assets and lease liabilities | 14,452 | 1,139 | ||||
| Gain from sale and dispositions of patient service equipment, property and equipment | (5,353) | (15,619) | ||||
| Changes in operating assets and liabilities: | ||||||
| Accounts receivable, net | 111,613 | (74,963) | ||||
| Merchandise inventories | (274,589) | (35,412) | ||||
| Accounts payable | 157,668 | 52,926 | ||||
| Net change in other assets and liabilities | (76,476) | (39,617) | ||||
| Other, net | 760 | 3,168 | ||||
| Cash used for operating activities | (35,066) | (52,962) | ||||
| Investing activities: | ||||||
| Additions to property and equipment | (55,697) | (45,997) | ||||
| Proceeds from sale of property and equipment | 16,884 | 49,538 | ||||
| Additions to computer software | (8,977) | (3,411) | ||||
| Other, net | (410) | (2,000) | ||||
| Cash used for investing activities | (48,200) | (1,870) | ||||
| Financing activities: | ||||||
| Borrowings under amended Receivables Financing Agreement | - | 205,000 | ||||
| Repayments under amended Receivables Financing Agreement | - | (139,300) | ||||
| Borrowings under Revolving Credit Facility | 776,984 | - | ||||
| Repayments under Revolving Credit Facility | (679,484) | - | ||||
| Repayments of term loans | - | (4,625) | ||||
| Repurchase of common stock | (1,503) | - | ||||
| Other, net | (3,219) | (7,755) | ||||
| Cash provided by financing activities | 92,778 | 53,320 | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 542 | (618) | ||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 10,054 | (2,130) | ||||
| Cash, cash equivalents and restricted cash at beginning of period | 49,382 | 272,924 | ||||
| Cash, cash equivalents and restricted cash at end of period (1) | $ | 59,436 | $ | 270,794 | ||
| Supplemental disclosure of cash flow information: | ||||||
| Income taxes paid, net | $ | 125 | $ | 2,365 | ||
| Interest paid | $ | 27,487 | $ | 18,211 | ||
| Noncash investing activity: | ||||||
| Unpaid purchases of property and equipment and computer software at end of period | $ | 81,085 | $ | 69,368 |
Summary Segment Information (unaudited)
(dollars in thousands)
| Three Months Ended March 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| % of | % of | ||||||||||
| consolidated | consolidated | ||||||||||
| Amount | net revenue | Amount | net revenue | ||||||||
| Net revenue: | |||||||||||
| Products & Healthcare Services | $ | 1,958,164 | 74.4 | % | $ | 1,974,837 | 75.6 | % | |||
| Patient Direct | 673,884 | 25.6 | % | 637,843 | 24.4 | % | |||||
| Consolidated net revenue | $ | 2,632,048 | 100.0 | % | $ | 2,612,680 | 100.0 | % | |||
| % of segment | % of segment | ||||||||||
| Operating income: | net revenue | net revenue | |||||||||
| Products & Healthcare Services | $ | 1,153 | 0.06 | % | $ | 11,486 | 0.58 | % | |||
| Patient Direct | 60,141 | 8.92 | % | 45,879 | 7.19 | % | |||||
| Acquisition-related charges and intangible amortization | (29,674) | (20,313) | |||||||||
| Exit and realignment charges, net | (31,226) | (27,356) | |||||||||
| Litigation and related charges (1) | (270) | - | |||||||||
| Consolidated operating income | $ | 124 | $ | 9,696 | |||||||
| Depreciation and amortization: | |||||||||||
| Products & Healthcare Services | $ | 10,833 | $ | 11,547 | |||||||
| Patient Direct | 35,334 | 36,465 | |||||||||
| Intangible amortization | 13,785 | 20,289 | |||||||||
| Other (2) | 1,201 | 5,794 | |||||||||
| Consolidated depreciation and amortization | $ | 61,153 | $ | 74,095 | |||||||
| Capital expenditures: | |||||||||||
| Products & Healthcare Services | $ | 17,716 | $ | 8,250 | |||||||
| Patient Direct | 46,958 | 41,158 | |||||||||
| Consolidated capital expenditures | $ | 64,674 | $ | 49,408 | |||||||
| Adjusted EBITDA (non-GAAP) | |||||||||||
| Products & Healthcare Services | $ | 24,218 | $ | 32,972 | |||||||
| Patient Direct | 97,637 | 83,298 | |||||||||
| Consolidated Adjusted EBITDA (non-GAAP) | $ | 121,855 | $ | 116,270 |
Net Loss Per Common Share (unaudited)
(dollars in thousands, except per share data)
| Three Months Ended March 31, | ||||||
| 2025 | 2024 | |||||
| Net loss | $ | (24,982) | $ | (21,886) | ||
| Weighted average shares outstanding - basic | 77,272 | 76,319 | ||||
| Dilutive shares | - | - | ||||
| Weighted average shares outstanding - diluted | 77,272 | 76,319 | ||||
| Net loss per common share: | ||||||
| Basic | $ | (0.32) | $ | (0.29) | ||
| Diluted | $ | (0.32) | $ | (0.29) |
Share-based awards for the three months ended March 31, 2025 and 2024 of approximately 1.8 million and 1.6 million shares were excluded from the calculation of net loss per diluted common share as the effect would be anti-dilutive.
GAAP/Non-GAAP Reconciliations (unaudited)
(dollars in thousands, except per share data)
The following table provides a reconciliation of reported operating income, net loss and net loss per common share to non-GAAP measures used by management.
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Operating income, as reported (GAAP) | $ | 124 | $ | 9,696 | |||
| Acquisition-related charges and intangible amortization (1) | 29,674 | 20,313 | |||||
| Exit and realignment charges, net (2) | 31,226 | 27,356 | |||||
| Litigation and related charges (3) | 270 | - | |||||
| Operating income, adjusted (non-GAAP) (Adjusted Operating Income) | $ | 61,294 | $ | 57,365 | |||
| Operating income as a percent of net revenue (GAAP) | 0.00 | % | 0.37 | % | |||
| Adjusted operating income as a percent of net revenue (non-GAAP) | 2.33 | % | 2.20 | % | |||
| Net loss, as reported (GAAP) | $ | (24,982) | $ | (21,886) | |||
| Pre-tax adjustments: | |||||||
| Acquisition-related charges and intangible amortization (1) | 29,674 | 20,313 | |||||
| Exit and realignment charges, net (2) | 31,226 | 27,356 | |||||
| Litigation and related charges (3) | 270 | - | |||||
| Other (4) | 424 | 430 | |||||
| Income tax benefit on pre-tax adjustments (5) | (18,539) | (11,348) | |||||
| Net income, adjusted (non-GAAP) (Adjusted Net Income) | $ | 18,073 | $ | 14,865 | |||
| Net loss per common share, as reported (GAAP) | $ | (0.32) | $ | (0.29) | |||
| After-tax adjustments: | |||||||
| Acquisition-related charges and intangible amortization (1) | 0.26 | 0.20 | |||||
| Exit and realignment charges, net (2) | 0.29 | 0.28 | |||||
| Litigation and related charges (3) | - | - | |||||
| Other (4) | - | - | |||||
| Net income per common share, adjusted (non-GAAP) (Adjusted EPS) | $ | 0.23 | $ | 0.19 |
GAAP/Non-GAAP Reconciliations (unaudited), continued
(dollars in thousands)
The following tables provide reconciliations of net loss, total debt and capital expenditures to non-GAAP measures used by management.
| Three Months Ended March 31, | ||||||
| 2025 | 2024 | |||||
| Net loss, as reported (GAAP) | $ | (24,982) | $ | (21,886) | ||
| Income tax benefit | (10,092) | (5,226) | ||||
| Interest expense, net | 33,959 | 35,655 | ||||
| Acquisition-related charges and intangible amortization (1) | 29,674 | 20,313 | ||||
| Exit and realignment charges, net (2) | 31,226 | 27,356 | ||||
| Other depreciation and amortization (6) | 46,168 | 48,014 | ||||
| Stock compensation (7) | 6,598 | 6,176 | ||||
| LIFO charges (8) | 8,610 | 5,438 | ||||
| Litigation and related charges (3) | 270 | - | ||||
| Other (4) | 424 | 430 | ||||
| Adjusted EBITDA (non-GAAP) | $ | 121,855 | $ | 116,270 |
| March 31, | December 31, | ||||
| 2025 | 2024 | ||||
| Total debt, as reported (GAAP) | $ | 1,947,462 | $ | 1,853,596 | |
| Cash and cash equivalents | (59,436) | (49,382) | |||
| Net debt (non-GAAP) | $ | 1,888,026 | $ | 1,804,214 |
| Three Months Ended March 31, | ||||||
| 2025 | 2024 | |||||
| Capital expenditures, as reported (GAAP) | $ | 64,674 | $ | 49,408 | ||
| Proceeds from sale of property and equipment (9) | (16,884) | (49,538) | ||||
| Net capital expenditures (non-GAAP) (Net Capex) | $ | 47,790 | $ | (130) |
The following items have been excluded in our non-GAAP financial measures:
(1) Acquisition-related charges consist primarily of one-time costs related to the planned acquisition of Rotech Healthcare Holdings Inc. (Rotech), which consisted primarily of legal and professional fees. For the three months ended March 31, 2025, we incurred $16 million of acquisition-related costs. We incurred no acquisition related charges for the three months ended March 31, 2024. Acquisition-related charges and intangible amortization also include amortization of intangible assets established during acquisition method of accounting for business combinations. Acquisition-related charges consist primarily of one-time costs related to acquisitions, including transaction costs necessary to consummate acquisitions, such as advisory fees and legal fees, director and officer tail insurance expense, as well as transition costs, such as severance and retention bonuses, information technology (IT) integration costs and professional fees. These amounts are highly dependent on the size and frequency of acquisitions and are being excluded to allow for a more consistent comparison with forecasted, current and historical results.
(2) Exit and realignment charges, net were $31 million for the three months ended March 31, 2025. These charges primarily related to (1) kitting and manufacturing initiatives of $10 million (2) professional fees associated with the potential sale of our P&HS segment of $7.1 million, (3) an accounts receivable provision of $6.8 million associated with Fusion 5, which is no longer operating (4) $5.7 million in professional fees associated with Patient Direct strategic initiatives and (5) $1.5 million of other charges. Exit and realignment charges, net were $27 million for the three months ended March 31, 2024. These charges primarily related to (1) the 2023-2024 Operating Model Realignment Program of
$33 million, including professional fees, severance, and other costs to streamline functions and processes and (2) costs related to IT strategic initiatives such as converting certain divisions to common IT systems of $1.2 million partially offset by (3) a $7.4 million gain on the sale of our corporate headquarters. These costs are not normal recurring, cash operating expenses necessary for the Company to operate its business on an ongoing basis.
(3) Litigation and related charges includes settlement costs and related charges of legal matters within our Patient Direct segment. These costs do not occur in the ordinary course of our business and are inherently unpredictable in timing and amount.
(4) For the three months ended March 31, 2025 and 2024, other includes interest costs and net actuarial losses related to our frozen noncontributory, unfunded retirement plan for certain retirees in the United States (U.S.).
(5) These charges have been tax effected by determining the income tax rate depending on the amount of charges incurred in different tax jurisdictions and the deductibility of those charges for income tax purposes.
(6) Other depreciation and amortization relates to property and equipment and capitalized computer software, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges.
(7) Stock compensation includes share-based compensation expense related to our share-based compensation plans, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges.
(8) LIFO charges includes non-cash adjustments to merchandise inventories valued at the lower of cost or market, with the approximate cost determined by the last-in, first-out (LIFO) method for distribution inventories in the U.S. within our Products & Healthcare Services segment.
(9) Proceeds from sale of property and equipment for the three months ended March 31, 2024 includes $34 million in gross proceeds related to the sale of our corporate headquarters.
Use of Non-GAAP Measures
This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). In general, the measures exclude items and charges that (i) management does not believe reflect Owens & Minor, Inc.'s (the Company) core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods without predictable trends. Management uses these non-GAAP financial measures internally to evaluate the Company's performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation.
Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company's performance to that of its competitors. However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
The non-GAAP financial measures disclosed by the Company should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated.
Jackie Marcus or Nick Teves
Executive Vice President & Chief Financial Officer
SOURCE: Owens & Minor, Inc.